Introduction：

Afatinib is a second-generation irreversible tyrosine kinase inhibitor (TKI), mainly used for the treatment of non-small cell lung cancer (NSCLC). It blocks the growth and division of tumor cells by inhibiting the signaling pathways of epidermal growth factor receptor (EGFR/HER1), human epidermal growth factor receptor 2 (HER2/HER2), and HER4.

Indications：

EGFR Mutation-Positive Non-Small Cell Lung Cancer

First-Line Treatment: It is applicable to patients with locally advanced or metastatic NSCLC who have sensitive EGFR mutations (such as exon 19 deletion, exon 21 L858R mutation), especially those who have not received EGFR-TKI treatment.

Second-Line Treatment: It can be used for locally advanced or metastatic squamous NSCLC that progresses during or after platinum-containing chemotherapy.

Other HER2-Related Tumors

Currently, it is also being explored for use in breast cancer, gastric cancer, etc. with HER2 mutations, but these are not the primary indications.

Recommended dosage: 

Take orally once a day, 40 mg each time, and take it on an empty stomach (1 hour before meals or 2 hours after meals).